Greenwich LifeSciences, Inc.
GLSIHealthcareNASDAQBiotechnology · Last scanned Jun 3, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Greenwich LifeSciences, Inc. focuses on Biotechnology services and products. Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States and Romania. The company carries a $356.5M market cap, placing it firmly in the small-cap category. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.
Market Cap
$356.5M
Beta
1.39
P/E (TTM)
—
P/E (Fwd)
-29.62
EPS (TTM)
$-1.43
EPS (Fwd)
$-0.82
ROE
-543.4%
ROA
-254.2%
Cash
$3.8M
Total Debt
$0
Free CF
-$1.4M
52W Change
160.1%
Annual Financials
Cash vs Debt
Greenwich LifeSciences, Inc. reports $3.8M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$1.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -543.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing GLSI's risk profile alongside its fundamentals and technical indicators provides a more complete picture.